Ileus Clinical Trial
Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Post Operative Ileus After Ventral Hernia Repair
Verified date | August 2019 |
Source | Bausch Health Americas, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the safety and efficacy of two different dose regimens (12 milligrams [mg] and 24 mg) of IV MOA-728 versus placebo in shortening the time to return of bowel function in participants receiving opioid analgesia administered via patient-controlled anesthesia (PCA), and who had undergone repair of large (greater than or equal to [≥]10 centimeters) ventral hernias with or without a mesh prosthesis via laparotomy or laparoscopy.
Status | Completed |
Enrollment | 374 |
Est. completion date | February 5, 2008 |
Est. primary completion date | February 5, 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Males and females, ages 18 and older. - Scheduled for ventral wall hernia repair with general anesthesia. - Meets the American Society of Anesthesiologists physical status I, II, or III. Exclusion Criteria: - Received investigational drug or procedure within 30 days of randomization. - Women who are pregnant or lactating. - Calculated creatinine clearance (Cockcroft-Gault glomerular filtration rate [GFR] formula) less than or equal to (</=) 50 milliliters/minute (mL/min). |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Kangnam-Gu | Seoul |
Lead Sponsor | Collaborator |
---|---|
Bausch Health Americas, Inc. | Progenics Pharmaceuticals, Inc. |
United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to First Bowel Movement | Time to first bowel movement was measured from the end of surgery (defined as the time when the last skin suture or staple was placed in the participant). Time of the first bowel movement was recorded on the electronic case report form (eCRF). The first bowel movement was defined as a normal stool for a postoperative participant based on the clinical judgment of the investigator or designee. Analysis was performed by Kaplan-Meier estimate. Participants who had a bowel movement but were readmitted to the hospital within 1 week after discharge with a diagnosis of postoperative ileus (POI) were considered censored at the time of the first bowel movement as if the bowel movement had not occurred. | Day 1 (From the time of end of surgery [that is; from the first dose of study drug administration]) up to Day 10 | |
Secondary | Time to Discharge Eligibility | Time to discharge eligibility was measured from the end of surgery (defined as the time when the last skin suture or staple was placed in the participant). Discharge eligibility was defined as tolerance of oral intake of liquids greater than (>) 500 milliliters (mL) per 8 hours without nausea or retching/vomiting. Analysis was performed by Kaplan-Meier estimate. | Day 1 (From the time of end of surgery [that is; from the first dose of study drug administration]) up to Day 10 | |
Secondary | Time to Discharge Order Written From the End of Surgery | The investigator or designee recorded the time of the order. Participants re-admitted to the hospital with a diagnosis of POI within 7 days after discharge was considered treatment failures. Analysis was performed by Kaplan-Meier estimate. | Day 1 (From the time of end of surgery [that is; from the first dose of study drug administration]) up to Day 10 | |
Secondary | Number of Participants With Clinically Meaningful Events (CMEs) for Nausea or Retching/Vomiting at Day 2 (24 Hours) as Evaluated by the Opioid-Related Symptom Distress Scale (SDS) | CMEs were defined using opioid-related SDS (assessed participant-reported levels of severity concerning 10 symptoms associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion and retching/vomiting). CME = any symptom rated as severe (3) or very severe (4), with the exception of confusion. A total CME score was calculated by summing the number of CMEs across symptoms and ranged from 0 to 9. CME was counted for either nausea or vomiting/retching, or both and reported in this outcome measure. | Day 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00065234 -
Acupuncture to Prevent Postoperative Bowel Paralysis (Paralytic Ileus)
|
Phase 2 | |
Completed |
NCT01156129 -
Interventions to Decrease the Impact of Post-OPerative Ileus After Liver Transplant or Resection Surgery
|
Phase 1 | |
Recruiting |
NCT05712525 -
Gut Recovery In Patients Following Surgery
|
||
Completed |
NCT06338813 -
Digital Manometry for Intra-Abdominal Pressure Measurement in Ileus
|
N/A | |
Recruiting |
NCT05315765 -
Development of a Patient Reported Outcome Measure for GastroIntestinal Recovery
|
||
Completed |
NCT02161367 -
Effect of Simethicone on Postoperative Ileus in Patients Undergoing Colorectal Surgery
|
Phase 4 | |
Completed |
NCT03711487 -
The Effect of Foeniculum Vulgare Ironing on Gastrointestinal Recovery After Colorectal Resection
|
Phase 2 | |
Not yet recruiting |
NCT04001985 -
Nasogastric Tube Clamping Trial vs. Immediate Removal
|
N/A | |
Completed |
NCT02836470 -
A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection
|
Phase 2 | |
Completed |
NCT04100447 -
A Study to Evaluate the Safety, Tolerability and Efficacy of LB1148 for Subjects Undergoing Elective Bowel Resection
|
Phase 1 | |
Active, not recruiting |
NCT03795467 -
Peripheral Perfusion Index, Haemoglobin and Blood Transfusion in Acute Surgical Patients
|
||
Completed |
NCT01143259 -
Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use
|
N/A | |
Terminated |
NCT03352414 -
Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC
|
Phase 2 | |
Not yet recruiting |
NCT04305730 -
Use of Pedometer Following Radical Cystectomy
|
N/A | |
Completed |
NCT02760290 -
Comparison of Extraperitoneal and Intraperitoneal Cesarean Technique
|
N/A | |
Active, not recruiting |
NCT02399605 -
Subcutaneous Electrical Stimulation in the Prevention of Postoperative Ileus
|
N/A | |
Completed |
NCT00388258 -
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus
|
Phase 3 | |
Terminated |
NCT05470387 -
A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection
|
Phase 3 | |
Completed |
NCT00205842 -
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus
|
Phase 3 | |
Enrolling by invitation |
NCT05298774 -
Myoelectric Activity Following Colorectal Surgery and Return of Bowel Function
|
N/A |